Post-COVID Hypercoagulability: Implications for Perioperative Anticoagulation and Thromboembolism Prevention in Surgical Patients

Introduction

Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, is associated with a profound and unique coagulopathy distinct from classical disseminated intravascular coagulation. This prothrombotic state, characterized by elevated D-dimer, fibrinogen, and endothelial injury, may persist for months after clinical recovery, complicating perioperative management decisions for surgical patients.

As the pandemic evolves into its endemic phase, increasing numbers of recovered COVID-19 patients are presenting for elective and urgent surgeries. Understanding the long-term thrombotic risk and optimizing perioperative anticoagulation strategies is critical for improving surgical outcomes in this population.

Pathophysiology of Post-COVID Hypercoagulability

Post-COVID hypercoagulability arises from several overlapping mechanisms:

• Endothelial Dysfunction: SARS-CoV-2 directly infects endothelial cells, causing endotheliitis and persistent microvascular injury.

• Platelet Activation and Thrombin Generation: Sustained platelet hyperreactivity and activation of the coagulation cascade led to elevated thrombin generation even months after recovery.

• Elevated Biomarkers: D-dimer, fibrinogen, and von Willebrand factor remain elevated in convalescent patients,reflecting ongoing vascular inflammation.

These factors collectively result in a state of increased thrombotic potential that may not be captured by conventional perioperative risk scores.

Clinical Evidence of Thrombotic Risk in Post-COVID Patients

Several large-scale studies and meta-analyses have confirmed an elevated risk of VTE in patients recently recovered from COVID-19:

• Patell et al. reported a post-discharge VTE incidence of 0.6% and bleeding rate of 3.7% in 163 hospitalized COVID-19 patients.

• Giannis et al. (CORE-19 registry) demonstrated a 90-day cumulative thromboembolic rate of 2.5%, comparable to medically ill patients with non-COVID illnesses.

• A systematic review by Zuin et al. estimated the post-acute VTE incidence at approximately 2%, with higher risks observed in ICU survivors.

While most data are from non-surgical cohorts, the extrapolation of this risk to perioperative settings suggests the need for heightened vigilance in surgical patients.

Perioperative Anticoagulation Considerations

Evidence to guide perioperative anticoagulation in post-COVID patients remains limited. However, the following principles can be drawn:

1. Preoperative Risk Stratification:

• Recent COVID-19 illness (within 3 months), persistent symptoms, elevated D- dimer (>500 ng/mL), and ICU stay are potential risk enhancers.

2. Biomarker-Guided Prophylaxis:

• Persistent elevation in D-dimer may indicate ongoing risk; however, no prospective trials validate routine preoperative D-dimer testing.

3. Thromboprophylaxis Strategy:

• Standard LMWH or DOAC dosing is recommended perioperatively, with consideration of intensified prophylaxis in patients with additional risk factors (e.g., cancer, immobility, prior VTE).

4. Extended Prophylaxis:

• The MICHELLE trial demonstrated that 35-day rivaroxaban reduced VTE risk in high-risk post-discharge COVID-19 patients without significantly increasing bleeding.

                                                 Table 1: Perioperative Anticoagulation Considerations in Post-COVID Patients

Risks of Bleeding Versus Thrombosis

Balancing VTE prevention with bleeding risk is critical:

• Post-discharge bleeding rates (~3.7%) are comparable to thrombosis rates (~2.5%).

• The MICHELLE trial showed no significant rise in major bleeding with extended rivaroxaban prophylaxis, but this finding may not generalize to surgical patients.

Individualized assessment remains paramount, pending surgery- specific outcome data.

Current Guideline Recommendations

The ISTH and CHEST guidelines recommend prophylactic-dose anticoagulation for hospitalized COVID-19 patients but acknowledge insufficient data for post-discharge or surgical populations. Similarly, the American College of Chest Physicians suggests cautious extended prophylaxis in high-risk individuals.

Future Directions

Emerging research areas include:

• Biomarker-driven risk models: Validating perioperative D-dimer thresholds.

• Perioperative VTE trials: Evaluating the safety and efficacy of extended DOAC prophylaxis in post-COVID surgical patients.

• Enhanced ERAS protocols: Integrating COVID history into enhanced recovery after surgery guidelines.

Conclusion

Post-COVID hypercoagulability presents new challenges for perioperative management. While evidence is still evolving, cli-nicians should adopt individualized thromboprophylaxis strategies incorporating COVID history, biomarker trends, and patient-spe-cific risk factors. Prospective trials are urgently needed to optimize care pathways in this growing patient population [1-10].

Author Disclosures

Author Contributions

I, Brendan Jones, conceptualized the review, conducted the literature search, synthesized the findings, and wrote the manuscript.

Conflict of Interest

The author declares no conflicts of interest. Funding: No external funding was received for this work.

Use of AI Tools

This manuscript was prepared with the assistance of AI language models to enhance clarity, grammar, and structure. All intellectual content, critical analysis, and interpretation of data remain the sole responsibility of the author.

References